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Abstract
Background: Hypoxia inducible factor 1-alpha (HIF1A) is a transcription factor that plays important role in
regulating cascade of reactions. In this study, the effect of rs11549465 (1772 C/T) and rs11549467 (1790 G/A)
polymorphisms of HIF1A gene and its association with cancers were investigated through meta-analysis.
Methods: Meta-analysis of genome wide association studies of HIF1A 1772 C/T polymorphism were conducted on
22 case-control studies of sample size 19024 and for 1790 G/A polymorphism 19 case-control studies were included
with sample size 10654. Genotype and allelic frequency compared between cases and controls together with
further subgroup analyses were carried out by cancer type and ethnicity.
Results: Meta-analysis from this study indicated that HIF1A 1772 C/T polymorphism is significantly associated with
overall cancer risk. T allele and genotype TT are significantly associated with increasing overall cancer risk; odds
ratios (OR) dominant model [TT + CT vs. CC: OR 1.30, 95 % CI (1.06-1.59), p-value: 0.0115], and T allele vs. C allele:
OR 1.32, 95 % CI (1.07-1.63), p-value: 0.0098. Also, HIF1A 1790 G/A polymorphism, analyses showed that A allele
and genotype AA are significantly associated with increasing overall cancer risk; odds ratios (OR) homozygote
comparison [AA vs. GG: OR 5.10, 95 % CI (3.12-8.33), p-value: <0.0001], heterozygote comparison [GA vs. GG:
OR 1.74, 95 % CI (1.20-2.52), p-value: 0.0033], dominant model [AA + GA vs. GG: OR 1.82, 95 % CI (1.26-2.62), p-value:
0.0014], recessive model [AA vs. GA + GG: OR 3.79, 95 % CI (2.34-6.15), p-value: <0.0001] and A allele vs. G allele:
OR 1.82, 95 % CI (1.31-2.52), p-value: 0.0003.
Conclusion: In detail meta-analysis indicated that both the polymorphisms 1772 C/T and 1790 G/A are significantly
associated with overall cancer risk. The subgroup analyses showed that lung cancer is significantly associated with
both polymorphisms. Although the 1772 C/T polymorphism is significantly associated with decreasing risk of renal
cell carcinoma but the 1790 G/A polymorphism has shown to significantly increase the cancer risk in both
Caucasian and Asian population. Thus, HIF1A could be a useful prognostic marker for cancers early predisposition.
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Background
Cancer is the second leading cause of morbidity and mor-
tality worldwide [1]. One major feature of cancer is un-
controlled cell proliferation, which can then invade
adjacent parts of the body and spread to other organs, the
latter process is referred as metastases, which are the
major cause of death from cancer [2]. The most common
causes of cancer deaths are due to cancers of the: lung
(1.59 million deaths), liver (745,000 deaths), stomach
(723,000 deaths), colorectal (694,000 deaths), breast
(521,000 deaths) and esophageal (400,000 deaths) [1, 2].
Alongside, metabolic alterations and tumor hypoxia have
consistently been identified as classical features with
aggressive malignancy [3, 4]. Hypoxia regulates tumor cell
phenotype mainly by altering genes that are sensitive
to oxygen pressure [5]. However, the exact mechanism
of carcinogenesis is yet to be elucidated. In recent
years, an increasing number of studies have focused on
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understanding the relationship between genetic factors
and cancer risk [3, 4]. Through the years, it has become
well accepted that single nucleotide polymorphisms
(SNPs) are the most common and effective type of genetic
variations studied in association with disease susceptibility
and are the markers of many complex diseases [6].
Hypoxia inducible factor 1α (HIF1A), is a transcription
factor that has major impacts in the process of develop-
ment and progression of cancers [7]. HIF1A regulates
the expression of over 100 genes that control the major
cellular functions including apoptosis, cell proliferation,
glucose metabolism, erythropoiesis, iron metabolism and
angiogenesis. It is a master regulator of oxygen homeosta-
sis [7]. In the scientific community, HIF1A has been a
research focus and a number of SNPs within HIF1A
gene have been identified in association with cancers,
with the most widely studied polymorphisms are
C1772T (rs11549465) and G1790A (rs11549467) poly-
morphisms [8–38]. These two SNPs are located within
the same domain (ODD/ pVHL) in exon 12 of the
HIF1A gene [8, 9]. Recently a meta-analysis has revealed
that C1772T is not in substantial linkage disequilibrium
(LD) with G1790A [38]. A number of studies have sug-
gested that these two nonsynonymous mutations might
alter the transcriptional activity of HIF1A gene by caus-
ing structural changes with varied stability, which in
turn, might influence the downstream target genes ex-
pression and regulation [8, 9, 38]. In the recent years, a
good number of studies have investigated the impact of
HIF1A polymorphisms on cancer risk in different popula-
tions; however reported results varied across studies and
remain inconclusive [10–38]. In this study, the effect of
rs11549465 (1772 C/T) and rs11549467 (1790 G/A) poly-
morphisms of HIF1A gene and its association with can-
cers were investigated systematically through meta-
analysis.
Methods
Search study and study selection
The PubMed, PubMed Central and Google Scholar data-
bases were searched systematically to retrieve compatible
and pertinent peer reviewed publications of empirical stud-
ies. Published articles of last 15 years (ended on December
2014), in English language were only considered for this
study. The search terms included were (1) HIF1A, (2)
GWAS, (3) SNPs, (4) polymorphisms, (5) C1772T/ P582S,
(6) A1790G/ A588T, (7) case-control study, and (8) cancer.
Eligibility criteria
Two authors independently investigated titles and ab-
stracts of all the articles. Irrelevant and incompatible
studies were excluded primarily. For final review, crite-
ria’s for further study elimination were: if (1) the study
population was not defined completely; (2) it is not a
case-control study; (3) not a genome wide association
study; (4) incomplete information of allele frequency;
and (5) the year of study conducted was not specified.
Also, reviews, editorials, meta-analysis and non-human
researches were excluded. Only case-control studies,
genome wide association study (GWAS) and human re-
searches were considered for the final review. Further,
the references of the selected studies were screened
carefully for incorporation of additional relevant studies.
Only English language articles were considered for this
study. Discrepancies and difficulties were discussed with
corresponding authors where necessary. Following infor-
mation were extracted from each study: (1) authors
name, (2) year of study, (3) ethnicity of the study sub-
jects, (4) cancer type and (5) allelic frequency (Fig. 1).
Meta-analysis
For HIF1A 1772 C/T polymorphism 22 case-control
studies were included of sample size 19024 and for
1790 G/A polymorphism 19 case-control studies were
included with sample size 10654. The meta-analysis was
prepared in accordance with PRISMA statement [39].
Statistical analysis
Meta-analysis of genome wide association studies
(GWAS) of HIF1A were conducted for two polymor-
phisms, 1772 C/T and 1790 G/A using odds ratios
(ORs). A slightly amended estimator of OR was used to
avoid the computation of reciprocal of zeros among ob-
served values in the calculation of the original OR [40].
Pooled ORs with 95 % CIs were calculated using ran-
dom effects model (REM) incorporating the inverse
variance weighted method [41]. Heterogeneity among
studies was assessed using the Q statistic [42] and
quantified using I^2 index [43]. Subgroup analyses were
carried out by cancer type and ethnicity. The Hardy
Weinberg Equilibrium (HWE) test was performed for
the controls of each study. The studies with control not in
HWE were supervised for sensitivity analysis. Publication
bias was assessed visually by conventionally constructed
funnel plot where the inverse of the standard error (1/se)
of the effect estimates were plotted against the logarithm
transformation of Odds Ratios [log(OR)] [44]. Further-
more, Egger’s test was performed to provide quantitative
evidence of publication bias [45]. “Gap: Genetic analysis
package” was used to perform the Hardy Weinberg Equi-
librium (HWE) test [46, 47]. All analyses were conducted
using “meta” package in R environment [46].
Summary measures
Odds Ratios (OR) with a 95 % confidence interval (CI)
were calculated to evaluate the genotype contrasts. The
genotype contrasts for the HIF1A 1772 C/T polymor-
phisms were: homozygote comparison [TT versus CC],
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heterozygote comparison [CT versus CC], and dominant
model [TT + CT versus CC], recessive model [TT versus
CT + CC] and T allele versus C allele. For HIF1A 1772 C/
T polymorphism, three studies were found with genotype
information of CC and CT +TT. These three studies were
included only to evaluate genotype contrast of dominant
model [TT + CT vs. CC]. The genotype contrasts for the
HIF1A 1790 G/A polymorphism were: homozygote com-
parison [AA versus GG], heterozygote comparison [GA
versus GG] and dominant model [AA +GA versus GG],




In the meta-analysis of the HIF1A 1772 C/T polymorph-
ism, ten different types of cancers consisted of 22 studies
with 8149 cancer cases and 10,875 controls were included.
Fig. 1 Flow diagram of study selection for HIF1A 1772 C/T and 1790 G/A polymorphisms; where “n” in the boxes is the number of
corresponding studies
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The types of cancer included in these studies were pros-
tate cancer, colorectal cancer, renal cell carcinoma, breast
cancer, lung cancer, oral squamous cell carcinoma
(OSCC), head-neck cancer, cervical cancer, bladder carcin-
oma and pancreatic cancer. For the following cancer
types: head-neck, cervical, bladder and pancreatic only
one study of each were found for the final review. So,
these cancer types with single studies were incorporated
in subgroup analysis as Other Cancers (Table 1).
For the meta-analysis of HIF1A 1790 G/A poly-
morphism, 19 studies with eleven different cancer types
consisted of 4681 cancer cases and 5973 controls were
included. The cancer types associated with this poly-
morphism were: renal cancer, prostate cancer, breast
cancer, lung cancer, oral squamous cell carcinoma
(OSCC), head-neck cancer, gastric cancer, hepatocellu-
lar carcinoma, lymph node metastasis, pancreatic can-
cer and colorectal cancer. For final review, only one
study of each of the following cancer types was found:
head-neck cancer, gastric cancer, hepatocellular carcin-
oma, lymph node metastasis, pancreatic cancer and
colorectal cancer. These cancer types with single stud-
ies were incorporated in subgroup analysis as Other
Cancers (Table 2).
Association of the HIF1A 1772 C/T polymorphism with
cancer risk
The pooled ORs for overall cancer suggested that the
HIF1A 1772 C/T polymorphism was significantly associ-
ated with increasing cancer risk for the dominant model
[TT + CT vs. CC: OR 1.30, 95 % CI (1.06-1.59), p-value:
0.0115] and [T vs. C allele: OR 1.32, 95 % CI (1.07-1.63),
p-value: 0.0098] (Fig. 2).
Subgroup analyses performed by cancer type
The subgroup analyses of prostate cancer, colorectal can-
cer, breast cancer and oral squamous-cell carcinoma sug-
gested no significant association of the HIF1A 1772 C/T
polymorphism. However, the subgroup analyses of renal
cell carcinoma suggested that the HIF1A 1772 C/T poly-
morphism is significantly associated with lowering renal
cell carcinoma risk in homozygote comparison [TT vs.
CC: OR 0.27, 95 % CI (0.08-0.90), p-value:0.0335]. Inter-
estingly, the results of subgroup analyses of lung cancer
suggested that the HIF1A 1772 C/T polymorphism is
highly associated with increasing lung cancer risk in
homozygote comparison [TT vs. CC: OR 4.88, 95 % CI
(2.42-9.84), p-value: <0.0001], recessive model [TT vs.
CT + CC: OR 4.04, 95 % CI (2.02-8.08), p-value:<0.0001].
Table 1 Characteristic of eligible studies included in meta-analysis of HIF1A 1772 C/T polymorphism
Study Year Country Ethnicity Cancer Case/Control HWE
Clifford et al. [8] 2001 UK Caucasian Renal cell carcinoma 35/143 0.018 (N)
Tanimoto et al. [9] 2003 Japanese Asian Head-neck cancer 55/110 0.545 (Y)
Ollerenshawa et al. [10] 2004 European Caucasian Renal cell carcinoma 160/162 <0.001 (N)
Chau et al. [11] 2005 USA Mixed Prostate cancer 196/196 <0.001 (N)
Franse et al. [12] 2006 Swedish Caucasian Colorectal cancer 198/258 0.916 (Y)
Konac et al. [13] 2007 Turkish Caucasian Cervical cancer 32/107 0.229 (Y)
Li et al. [14] 2007 American Mixed Prostate cancer 1041/1234 0.159 (Y)
Lee et al. [15] 2008 Korean Asian Breast cancer 1332/1369 0.250 (Y)
Kim et al. [16] 2008 Korean Asian Breast cancer 90/102 0.641 (Y)
Nadaoka et al.a [17] 2008 Japanese Asian Transitional cell carcinoma of bladder 219/461
Jacobs et al. [18] 2008 American Mixed Prostate cancer 1420/1450 0.041 (N)
Foley et al. [19] 2009 Ireland Caucasian Prostate cancer 95/188 0.623 (Y)
Morris et al. [20] 2009 Polish Caucasian Renal cell carcinoma 332/313 0.083 (Y)
Chen et al. [21] 2009 Taiwanese Asian Oral squamous cell carcinoma (OSCC) 174/347 0.722 (Y)
Shieh et al. [22] 2010 Taiwan Asian Oral squamous cell carcinoma (OSCC) 305/96 0.710 (Y)
Knechtel et al.a [23] 2010 Austria Caucasian Colorectal cancer 368/2156
Kang et al.a [24] 2011 Korean Asian Colorectal cancer 50/50
Putra et al. [25] 2011 Japanese Asian Lung cancer 83/110 0.545 (Y)
Wang et al. [26] 2011 Chinese Asian Pancreatic cancer 263/271 0.352 (Y)
Kuo et al. [27] 2012 Taiwanese Asian Lung cancer 285/300 0.132 (Y)
Li et al. [28] 2012 China Asian Prostate cancer 662/716 0.267 (Y)
Fraga et al. [29] 2014 Portuguese Caucasian Prostate cancer 754/736 0.400 (Y)
aFrequency of genotypes “CT + TT”. HWE Hardy-Weinberg Equilibrium
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The subgroup analyses of Other Cancers suggested that
the HIF1A 1772 C/T polymorphism is highly associated
with increasing Other Cancer risk in homozygote com-
parison [TT vs. CC: OR 27.20, 95 % CI (5.04-146.78), p-
value: 0.0001], heterozygote comparison [CT vs. CC: OR
2.16, 95 % CI (1.46-3.18), p-value: 0.0056], dominant
model [TT + CT vs. CC: OR 1.92, 95 % CI (1.17-3.14), p-
value: 0.0093], recessive model [TT vs. CT + CC: OR 17.5,
95 % CI (3.49-87.70), p-value: 0.0005] and [T vs. C allele:
OR 2.42, 95 % CI (1.55-3.77), p-value: <0.0001] (Table 3).
Subgroup analyses by ethnicity group
The analyses data for the HIF1A 1772 C/T polymorph-
ism suggested that there was no significant effect on the
Caucasian population. However, the subgroup analyses
of the Asian population suggested that the HIF1A 1772
C/T polymorphism was significantly associated with in-
creasing cancer risk in homozygote comparison [TT vs.
CC: OR 4.98, 95 % CI (2.66-9.31), p-value: <0.0001], het-
erozygote comparison [CT vs. CC: OR 1.30, 95 % CI
(1.01-1.69), p-value: 0.0455], dominant model [TT + CT
vs. CC: OR 1.41, 95 % CI (1.08-1.84), p-value: 0.0109],
recessive model [TT vs. CT + CC: OR 4.28, 95 % CI
(2.31-7.95), p-value:<0.0001] and [T vs. C allele: OR 1.43,
95 % CI (1.07-1.90), p-value: 0.0156] (Table 3). The sub-
group analyses of mixed ethnic groups suggested that
there were no significant association between HIF1A
1772 C/T polymorphism and cancer risk (Table 3).
Sources of heterogeneity
There were significant heterogeneity observed in the ana-
lyses of HIF1A 1772 C/T polymorphism for overall cancer
heterozygote comparison [CT vs. CC: Q = 69.67, d.f = 18,
p-value 0.0001, I^2 = 74.2 % (59.5 %-83.5 %)], dominant
model [TT + CT vs. CC: Q = 90.25, d.f = 21, p <0.0001,
I^2 = 76.7 % (65.1 %-84.5 %)], and [T vs. C allele: Q =
96.87, d.f = 18, p <0.0001, I^2 = 81.4 % (71.9 %-87.7 %). To
detect the sources of heterogeneity subgroup analyses by
cancer type and ethnicity group were performed. In the
subgroup analyses by cancer type heterogeneity was sig-
nificantly reduced. The results suggested that the studies
in prostate cancer, renal cell carcinoma, lung cancer,
Caucasian ethnicity and Asian ethnicity were the main
sources of heterogeneity (Additional file 1).
Association of the HIF1A 1790 G/A polymorphism with
cancer risk
The pooled ORs for overall cancer suggested that the
HIF1A 1790 G/A polymorphism was significantly associ-
ated with increasing cancer risk for homozygote compari-
son [AA vs. GG: OR 5.10, 95 % CI (3.12-8.33), p-value:
<0.0001, heterozygote comparison [GA vs. GG: OR 1.74,
95 % CI (1.20-2.52), p-value: 0.0033, dominant model
[AA +GA vs. GG: OR 1.82, 95 % CI (1.26-2.62), p-value:
0.0014], recessive model [AA vs. GA +GG: OR 3.79, 95 %
CI (2.34-6.15), p-value: <0.0001] and [A vs. G allele: OR
1.82, 95 % CI (1.31-2.52), p-value: 0.0003] (Fig. 3).
Table 2 Characteristic of eligible studies included in meta-analysis of HIF1A 1790G/A polymorphism
Study Year Country Ethnicity Cancer Case/Control HWE
Clifford et al. [8] 2001 Caucasian Caucasian Renal cancer 48/144 0.866(Y)
Tanimoto et al. [9] 2003 Japan Asian Head neck squeamish cell carcinoma 55/110 0.655(Y)
Ollerenshaw et al. [10] 2004 Caucasian Caucasian Renal cancer 146/288 <0.001(N)
Fransen et al. [12] 2006 Sweden Caucasian Colorectal cancer 198/256 0.775(Y)
Orr-Urtreger et al. [30] 2007 Israel Caucasian Prostate cancer 200/300 0.954(Y)
Li et al. [14] 2007 USA Mixed Prostate cancer 1066/1264 0.810(Y)
Apaydin et al. [31] 2008 Turkey Caucasian Breast cancer 102/102 0.840(Y)
Kim et al. [16] 2008 Korea Asian Breast cancer 90/102 0.06(Y)
Muñoz et al. [32] 2009 Spain Caucasian Oral squamous cell carcinoma 64/139 0.693(Y)
Chen et al. [21] 2009 Taiwanese Asian Oral squamous cell carcinoma 174/347 0.701(Y)
Morris et al. [20] 2009 polish Caucasian Renal cancer 325/309 0.662(Y)
Li K et al. [33] 2009 Tibetan Asian Gastric cancer 87/106 0.764(Y)
Hsiao et al. [34] 2010 Taiwan Asian Hepatocellular carcinoma 102/347 0.701(Y)
Putra et al. [25] 2011 Japan Asian Lung cancer 83/110 0.655(Y)
Wang et al. [26] 2011 Japan Asian Pancreatic cancer 263/271 0.486(Y)
Kuo et al. [27] 2012 China Asian Lung cancer 285/300 0.154(Y)
Li et al. [28] 2012 China Asian Prostate cancer 662/716 0.554(Y)
Mera-Mene et al. [35] 2012 Spain Caucasian Lymph node metastasis 111/139 0.693(Y)
Qin et al. [36] 2012 Asian Asian Renal cancer 620/623 0.411(Y)
HWE Hardy-Weinberg Equilibrium
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Fig. 2 Forest plot of HIF1A polymorphism 1772 C/T for overall cancer
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Table 3 Meta-analysis of the HIF1A 1772 C/T polymorphism association with cancer
TT vs. CC CT vs. CC TT + CT vs. CC TT vs. CT + CC T vs. C
Study number Sample size OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value
Overall cancer 22 19024 1.52 [0.73–3.18] 0.2648 1.23 [1.00–1.53] 0.0536 1.30 [1.06–1.59] 0.0115 1.64 [0.94–2.85] 0.0832 1.32 [1.07–1.63] 0.0098
Prostate cancer 6 8688 0.84 [0.47–1.49] 0.5449 1.34 [0.95–1.87] 0.0913 1.33 [0.95–1.87] 0.0982 0.81 [0.47–1.40] 0.4535 1.29 [0.94–1.76] 0.1178
Colorectal cancer 3 3080 1.91 [0.32–11.58] 0.4801 0.83 [0.50–1.39] 0.4817 1.24 [0.77–2.01] 0.3756 1.97 [0.33–11.90] 0.4603 0.94 [0.59–1.49] 0.7833
Renal cancer 3 1145 0.27 [0.08–0.90] 0.0335 0.40 [0.12–1.34] 0.1369 0.43 [0.15–1.20] 0.1082 1.08 [0.44–2.64] 0.8703 0.84 [0.58–1.22] 0.3548
Breast cancer 2 2893 5.18 [0.88–30.38] 0.0683 1.00 [0.77–1.29] 0.9964 1.05 [0.81–1.35] 0.7221 5.18 [0.88–30.36] 0.0684 1.09 [0.86–1.39] 0.4701
Lung cancer 2 778 4.88 [2.42–9.84] < 0.0001 1.56 [0.94–2.61] 0.088 1.67 [0.79–3.54] 0.1832 4.04 [2.02–8.08] < 0.0001 1.68 [0.77–3.64] 0.1908
OSCC 2 922 6.14 [0.25–151.49] 0.2673 1.29 [0.70–2.37] 0.4142 1.36 [0.75–2.49] 0.3127 6.01 [0.24–148.26] 0.2729 1.43 [0.79–2.56] 0.2348
Other cancers 4 1518 27.20 [5.04–146.78] 0.0001 2.16 [1.46–3.18] 0.0056 1.92 [1.17–3.14] 0.0093 17.5 [3.49 – 87.70] 0.0005 2.42 [1.55–3.77] < 0.0001
Ethnicity
Caucasian 8 6037 0.97 [0.24–3.93] 0.9654 1.09 [0.60–2.00] 0.7751 1.19 [0.75–1.89] 0.4528 1.48 [0.65–3.39] 0.352 1.31 [0.84–2.06] 0.237
Asian 11 7450 4.98 [2.66–9.31] < 0.0001 1.30 [1.01–1.69 0.0455 1.41 [1.08–1.84] 0.0109 4.28 [2.31–7.95] < 0.0001 1.43 [1.07–1.90] 0.0156












Fig. 3 Forest plot of the HIF1A polymorphism 1790 G/A for overall cancer
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Subgroup analyses by cancer type
The analyzed data of prostate cancer suggested no sig-
nificant association with the HIF1A 1790 G/A poly-
morphism. The subgroup analyses of renal cancer
suggested that the HIF1A 1790 G/A polymorphism was
significantly associated with increasing cancer risk for
homozygote comparison [AA vs. GG: OR 5.11, 95 % CI
(2.24-11.66), p-value: 0.0001], recessive model [AA vs.
GA +GG: OR 3.05, 95 % CI (1.36-6.84), p-value: 0.0068]
whereas the subgroup analyses of breast cancer showed
that the HIF1A 1790 G/A polymorphism was signifi-
cantly associated with decreasing cancer risk for [A vs. G
allele: OR 0.30, 95 % CI (0.09-1.00), p-value: 0.0495].
The subgroup analyses of lung cancer suggested that the
HIF1A 1790 G/A polymorphism was significantly associ-
ated with increasing cancer risk for homozygote com-
parison [AA vs. GG: OR 5.41, 95 % CI (2.74-10.69), p-
value: <0.0001], heterozygote comparison [GA vs. GG:
OR 1.76, 95 % CI (1.25-2.49), p-value: 0.0013], dominant
model [AA +GA vs. GG: OR 2.20, 95 % CI (1.60-3.03),
p-value:<0.0001], recessive model [AA vs. GA +GG: OR
4.51, 95 % CI (2.31-8.81), p-value:<0.0001] and [A vs. G
allele: OR 2.31, 95 % CI (1.77-3.02), p-value: <0.0001].
Also, the subgroup analyses of oral squamous cell car-
cinoma (OSCC) suggested that the HIF1A 1790 G/A
polymorphism was significantly associated with increas-
ing cancer risk for homozygote comparison [AA vs. GG:
OR 12.68, 95 % CI (1.43-112.64), p-value: 0.0227], het-
erozygote comparison [GA vs. GG: OR 4.69, 95 % CI
(1.96-11.21), p-value: 0.0005], dominant model [AA +
GA vs. GG: OR 5.17, 95 % CI (1.99-13.43), p-value:
0.0008], recessive model [AA vs. GA +GG: OR 10.12,
95 % CI (1.14-89.72), p-value: 0.0376] and [A vs. G allele:
OR 5.00, 95 % CI (2.10-11.97), p-value: 0.0003] (Table 4).
The subgroup analyses of Other Cancers suggested that
the HIF1A 1790 G/A polymorphism is highly associated
with increasing Other Cancer risk heterozygote compari-
son [GA vs. GG: OR 1.96, 95 % CI (1.05-3.65), p-value:
0.0336], dominant model [AA +GA vs. GG: OR 1.96,
95 % CI (1.05-3.67), p-value: 0.0341], and [A vs. G allele:
OR 1.91, 95 % CI (1.06-3.44), p-value: 0.0306] (Table 4).
Subgroup analyses by ethnicity group
For Caucasian population, the analyzed data suggested
that the HIF1A 1790 G/A polymorphism was highly as-
sociated with increasing cancer risk for homozygote
comparison [AA vs. GG: OR 5.68, 95 % CI (2.57-12.58),
p-value: <0.0001], recessive model [AA vs. GA +GG: OR
3.42, 95 % CI (1.57-7.45), p-value: 0.002]. For the Asian
population, the subgroup analyses of ethnicity group sug-
gested that the HIF1A 1790 G/A polymorphism was
highly associated with increasing cancer risk for homozy-
gote comparison [AA vs. GG: OR 4.76, 95 % CI (2.55-
8.91), p-value: <0.0001], heterozygote comparison [GA vs.
GG: OR 1.94, 95 % CI (1.38-2.72), p-value: 0.0001],
dominant model [AA + GA vs. GG: OR 2.04, 95 % CI
(1.44-2.87), p-value: <0.0001], recessive model [AA vs.
GA +GG: OR 4.05, 95 % CI (2.18-7.51), p-value: <0.0001]
and [A vs. G allele: OR 2.03, 95 % CI (1.46-2.81), p-value:
<0.0001] (Table 4).
Sources of heterogeneity
There were significant heterogeneity observed in the
analyses of HIF1A 1790G/A polymorphism for overall
cancer heterozygote comparison [GA vs. GG: Q = 77.05,
d.f = 18, p-value: <0.0001, I^2 = 76.6 % (63.8 %-84.9 %),
dominant model [AA + GA vs. GG: Q = 79.66, d.f = 18,
p-value: <0.0001, I^2 = 77.4 % (65.1 %-85.4 %)], and [A
vs. G allele: Q = 71.09, d.f = 18, p-value: <0.0001, I^2 =
74.7 % (60.4 %-83.8 %)]. To detect the sources of hetero-
geneity subgroup analyses by cancer type and ethnicity
group were performed. The results suggested that the
studies in renal cell carcinoma, oral squamous cell carcin-
oma (OSCC), Caucasian ethnicity and Asian ethnicity
were the main sources of heterogeneity (Additional file 2).
Publication bias
To investigate the evidence of publication bias of the
HIF1A 1772 C/T polymorphism for T versus C allele
and HIF1A 1790 G/A polymorphism for G versus A al-
lele funnel plot were used. The conventionally con-
structed funnel plot (log odds ratio [log(OR] vs 1/
standard error, 1/se) of HIF1A polymorphism 1772 C/T
for T vs. C allele suggested that there was evidence of
publication bias (Fig. 4). Also the funnel plot of HIF1A
polymorphism 1790 G/A for A vs. G allele suggested
that there was evidence of publication bias (Fig. 4).
However, the Egger’s linear regression analyses suggested
no evidence of significant publication bias in [T vs C al-
lele: t = 1.83, d.f = 17, p-value 0.0847] for HIF1A 1772 C/
T polymorphism. Also, for HIF1A 1790 G/A polymorph-
ism results showed no significant evidence of publication
bias in [A vs G allele: t = -1.87, d.f = 17, p-value 0.0787]
(Additional file 3).
Sensitivity analysis
Studies which were not in HWE were excluded to evaluate
the stability of the acquired results. The statistical signifi-
cance of the results was not shifted after omitting the
studies which were not in HWE which confirmed the ob-
tained results of the meta-analysis were stable and robust.
Conclusion
Results generated from this meta-analysis indicated that
both 1772 C/T and 1790 G/A polymorphisms are signifi-
cantly associated with increasing overall cancer risk. The
subgroup analyses by cancer type showed that both 1772 C/
T and 1790 G/A polymorphisms have significant association
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Table 4 Meta-analysis of the HIF1A 1790 G/A polymorphism association with cancer
AA vs. GG GA vs. GG AA vs. GA + GG AA + GA vs. GG A vs. G
Study number Sample size OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value
Overall 19 10654 5.10 [3.12–8.33] < 0.0001 1.74 [1.20–2.52] 0.0033 3.79 [2.34–6.15] < 0.0001 1.82 [1.26–2.62] 0.0014 1.82 [1.31–2.52] 0.0003
Renal cancer 4 2503 5.11 [2.24–11.66] 0.0001 1.51 [0.45–5.05] 0.5038 3.05 [1.36–6.84] 0.0068 1.58 [0.49–5.03] 0.442 1.53 [0.60–3.92] 0.3747
Prostate cancer 3 4208 3.35 [0.14–82.30] 0.4597 1.41 [0.96–2.08] 0.0822 3.25 [0.13–79.90] 0.4707 1.41 [0.93–2.15] 0.1043 1.42 [0.93–2.17] 0.1093
Breast cancer 2 396 0.36 [0.01–8.95] 0.5332 0.35 [0.10–1.24] 0.1045 0.37 [0.02–9.29] 0.5484 0.32 [0.09–1.10] 0.0702 0.30 [0.09–1.00] 0.0495
Lung cancer 2 778 5.41 [2.74–10.69] < 0.0001 1.76 [1.25–2.49] 0.0013 4.51 [2.31–8.81] < 0.0001 2.20 [1.60–3.03] < 0.0001 2.31 [1.77–3.02] < 0.0001
OSCC 2 724 12.68 [1.43–112.64] 0.0227 4.69 [1.96–11.21] 0.0005 10.12 [1.14–89.72] 0.0376 5.17 [1.99–13.43] 0.0008 5.00 [2.10–11.97] 0.0003
Other cancers 6 2045 3.77 [0.15–93.07] 0.4171 1.96 [1.05–3.65] 0.0336 3.10 [0.13–76.51] 0.4887 1.96 [1.05–3.67] 0.0341 1.91 [1.06–3.44] 0.0306
Ethnicity
Caucasian 8 2666 5.68 [2.57–12.58] < 0.0001 1.43 [0.54–3.74] 0.4691 3.42 [1.57–7.45] 0.002 1.50 [0.58–3.85] 0.3987 1.52 [0.68–3.42] 0.3103












with lung cancer, whereas these two polymorphisms showed
no significant association with prostate cancer. In oral squa-
mous cell carcinoma (OSCC) subgroup analyses data
showed that only 1790 G/A polymorphism has significant
association whereas the HIF1A 1772 C/T polymorphism
showed no significant association. However, the 1772 C/T
polymorphism has indicated significantly decreased risk in
renal cell carcinoma. Also, 1790 G/A polymorphism has in-
creased the cancer risk significantly in both Caucasian and
Asian ethnicity. Taken together all analyzed data, HIF1A
could be a prognostic marker useful for early detection and
diagnosis for cancers. In future, further experimental valida-
tions would be necessary to confirm the results.
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